CureVac advances talks to sell 405m COVID-19 vaccines to EU 24-Aug-2020 By Nick Taylor European Commission lines up deal to buy 405 million COVID-19 vaccines from CureVac, swelling stockpile to 1.5 billion doses.
MaaT starts manufacturing campaign after France lifts COVID-19-related restrictions 24-Aug-2020 By Nick Taylor Lifting of French restrictions on stool collection clears microbiome player MaaT Pharma to start new manufacturing campaign.
Analyst tips first wave of COVID-19 vaccines to generate $20b 20-Aug-2020 By Nick Taylor Bernstein's Ronny Gal tips leading vaccine developers to rack up sales of $20 million from COVID-19 shots in the first immunization wave.
AstraZeneca, J&J and Sanofi-GSK set to sell up to 1.1bn COVID-19 vaccines to EU 18-Aug-2020 By Nick Taylor European Union lines up deals to source up to 1.1 billion doses of three COVID-19 vaccines.
CDC tasks McKesson with distributing COVID-19 vaccines in US 18-Aug-2020 By Nick Taylor McKesson leverages existing link to US Centers for Disease Control and Prevention (CDC) to land $178 million COVID-19 vaccine.
AstraZeneca targets 25% jump in US flu vaccine shipments 17-Aug-2020 By Nick Taylor AstraZeneca increases US flu vaccine shipments by 25% to cope with anticipated surge in demand.
CureVac files for Nasdaq IPO to fund COVID-19 vaccine development 13-Aug-2020 By Nick Taylor CureVac files to raise upward of $200 million in Nasdaq IPO to fund clinical development of COVID-19 vaccine.
Moderna lands US COVID-19 vaccine contract worth up to $8bn 13-Aug-2020 By Nick Taylor US government inks deal to buy 100 million COVID-19 vaccine doses from Moderna for $1.5 billion, with more to follow.
Ligand inks $438m Pfenex buyout to add protein expression tech to portfolio 13-Aug-2020 By Nick Taylor Ligand Pharmaceuticals strikes deal to buy Pfenex for $438 million upfront in cash to gain control of protein expression technology.
Gates Foundation commits $150m to make COVID-19 vaccines for $3 a dose 11-Aug-2020 By Nick Taylor The Bill & Melinda Gates Foundation provides $150 million for production of $3 doses of COVID-19 vaccines.
COVID-19 drives 20% growth at Merck KGaA’s process solutions unit 11-Aug-2020 By Nick Taylor Rising demand for single-use and downstream products from developers of COVID-19 therapies and vaccines drives growth at Merck KGaA.
Moderna makes commercial case for COVID-19 vaccine amid price pressure 10-Aug-2020 By Nick Taylor Moderna Therapeutics reveals it is selling its COVID-19 vaccine for up to $37 a dose, well above the amount charged by some of its rivals.
Fate touts potential to make 15,000 cell therapy doses per cGMP run 10-Aug-2020 By Nick Taylor Fate Therapeutics touts potential to make cell therapies from renewable cell lines at scale after early production success.
Sanofi wins race to ship vaccines ahead of ‘record’ flu season 06-Aug-2020 By Nick Taylor Sanofi ships first influenza vaccines to US for 2020-2021 flu season that is tipped to generate record sales.
Emergent in $174m deal with AZ to expand manufacturing commitment 04-Aug-2020 By Ben Hargreaves Emergent will produce commercial scale drug substance for AZ’s potential vaccine for COVID-19.
